Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.

Most patients with early active relapsing-remitting MS treated with ocrelizumab did not see worse hand function or ambulation ...

The US FDA has approved ocrelizumab (Ocrevus, Genentech) intravenous infusion for children aged 10 years and older with relapsing-remitting multiple sclerosis (RRMS) who weigh at least 55 lbs (25 kg), ...

The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and ...

Symptoms and frequency of relapses vary widely from person to person with the most common form of multiple sclerosis — and doctors aren’t entirely sure why. But, what exactly does a relapse look like?

MRI and disability scores better identify cognitive decline in stable RRMS patients than blood biomarkers, according to a new ...

MS is due to the body’s defence system, or immune system, attacking the insulating cover of myelin that protects the nerves. This damages the nerves and impairs their ability to pass on electric ...

When you learn that you have MS, you'll have lots of questions about what to do next and how to manage the effects of this long-term disease. With your doctor's help, you can control your symptoms and ...

Relapsing-remitting multiple sclerosis (RRMS) is the most common kind of multiple sclerosis. Getting prompt treatment can help you manage your symptoms and make it less likely your MS will get worse.

The goal of this double-blind, adaptive, dose-ranging, phase 2 study was to assess safety, tolerability and dose-response characteristics of siponimod and its effects on brain MRI lesion activity in ...

Multiple sclerosis is a disorder of the immune system, where the myelin coating the nerve cells is damaged by antibodies formed by the defence system of the body. This affects the functioning of the ...